Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H; MARIPOSA Investigators. Cho BC, et al. Among authors: sethi s. N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26. N Engl J Med. 2024. PMID: 38924756 Clinical Trial.
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
Felip E, Cho BC, Gutiérrez V, Alip A, Besse B, Lu S, Spira AI, Girard N, Califano R, Gadgeel SM, Yang JC, Yamamoto S, Azuma K, Kim YJ, Lee KH, Danchaivijitr P, Ferreira CG, Cheng Y, Sendur MAN, Chang GC, Wang CC, Prabhash K, Shinno Y, Stroyakovskiy D, Paz-Ares L, Rodriguez-Cid JR, Martin C, Campelo MRG, Hayashi H, Nguyen D, Tomasini P, Gottfried M, Dooms C, Passaro A, Schuler M, Gelatti ACZ, Owen S, Perdrizet K, Ou SI, Curtin JC, Zhang J, Gormley M, Sun T, Panchal A, Ennis M, Fennema E, Daksh M, Sethi S, Bauml JM, Lee SH. Felip E, et al. Among authors: sethi s. Ann Oncol. 2024 Sep;35(9):805-816. doi: 10.1016/j.annonc.2024.05.541. Epub 2024 Jun 26. Ann Oncol. 2024. PMID: 38942080 Free article. Clinical Trial.
Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Vale CL, Godolphin PJ, Fisher DJ, Higgins JPT, McAleenan A, Spiga F, Tritschler T, de Barros E Silva PGM, Berg DD, Berger JS, Berry LR, Bikdeli B, Blondon M, Bohula EA, Cattaneo M, Colombo R, Coluccio V, DeSancho MT, Farkouh ME, Fuster V, Girardis M, Hochman JS, Jensen TP, Jha V, Jüni P, Kirtane AJ, Lawler P, Le Gal G, Lecumberri R, Lentz SR, Lopes RD, Lorenzi E, Marietta M, Miranda CH, Morici N, Morpeth SC, Morrow DA, McQuilten ZK, Muñoz-Rivas N, Neal MD, Pant S, Parikh SA, Perepu U, Sadeghipour P, Sethi S, Sholzberg M, Spyropoulos AC, Stone GW, Talasaz AH, Tong S, Totterdell J, Venkatesh B, Wu MA, Zarychanski R, Zuily S, Viry J, Rylance J, Adhikari NKJ, Diaz JV, Marshall JC, Sterne JAC, Murthy S. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, et al. Among authors: sethi s. Ann Intern Med. 2024 Dec 24. doi: 10.7326/ANNALS-24-00800. Online ahead of print. Ann Intern Med. 2024. PMID: 39715559 Review.
Placental Infections.
Khullar P, Hon JD, Sethi S, Kim J, Iqbal M, Chavez MR. Khullar P, et al. Among authors: sethi s. Clin Obstet Gynecol. 2024 Dec 18. doi: 10.1097/GRF.0000000000000919. Online ahead of print. Clin Obstet Gynecol. 2024. PMID: 39690484
2,238 results